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METHODOLOGY
Estimating malaria transmission 
intensity from Plasmodium falciparum 
serological data using antibody density models
Emilie Pothin1,2,3*, Neil M. Ferguson1, Chris J. Drakeley4 and Azra C. Ghani1
Abstract 
Background: Serological data are increasingly being used to monitor malaria transmission intensity and have 
been demonstrated to be particularly useful in areas of low transmission where traditional measures such as EIR and 
parasite prevalence are limited. The seroconversion rate (SCR) is usually estimated using catalytic models in which 
the measured antibody levels are used to categorize individuals as seropositive or seronegative. One limitation 
of this approach is the requirement to impose a fixed cut-off to distinguish seropositive and negative individuals. 
Furthermore, the continuous variation in antibody levels is ignored thereby potentially reducing the precision of the 
estimate.
Methods: An age-specific density model which mimics antibody acquisition and loss was developed to make full 
use of the information provided by serological measures of antibody levels. This was fitted to blood-stage antibody 
density data from 12 villages at varying transmission intensity in Northern Tanzania to estimate the exposure rate as 
an alternative measure of transmission intensity.
Results: The results show a high correlation between the exposure rate estimates obtained and the estimated SCR 
obtained from a catalytic model (r = 0.95) and with two derived measures of EIR (r = 0.74 and r = 0.81). Estimates of 
exposure rate obtained with the density model were also more precise than those derived from catalytic models.
Conclusion: This approach, if validated across different epidemiological settings, could be a useful alternative frame-
work for quantifying transmission intensity, which makes more complete use of serological data.
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Background
Malaria remains a leading cause of morbidity and mortal-
ity worldwide [1], with heterogeneous levels of endemic-
ity across the globe [2]. Measuring malaria transmission 
intensity is a key element of monitoring changes in trans-
mission and assessing the impact of anti-malaria inter-
ventions. The reference standard historically used for 
reporting malaria transmission intensity is the entomo-
logical inoculation rate (EIR), defined as the number of 
infectious bites per person per year (ibppy), estimated 
by catching mosquitoes most commonly using light-
traps and then dissecting these mosquitoes to estimate 
the sporozoite (infectious) rate. Despite its usefulness 
in providing a direct estimate of the force of infection, 
this method is time consuming, expensive and can lack 
precision, especially in low endemicity areas. The preva-
lence of individuals carrying the parasite—termed para-
site prevalence (PrP)—is an alternative measurement of 
malaria transmission intensity. This can be, estimated 
in cross-sectional surveys using microscopy, rapid diag-
nostic test (RDT), or increasingly using PCR methods 
to detect infection in individuals. This approach is in 
widespread use, with population-level representative 
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samples now undertaken in many malaria endemic 
areas as part of national Malaria Indicator Surveys [3]. 
However, although PrP can be estimated rapidly in 
populations, it is subject to seasonal variation (e.g. 30 % 
variation between the peak and trough in highly seasonal 
areas in West Africa [4]), is affected by anti-malarial 
treatment levels, requires highly skilled staff (for micros-
copy and PCR), and lacks precision in low endemicity 
settings.
Serological data, which measures antibody responses to 
one or more malaria specific antigens, offer an alternative 
means to estimate past exposure to malaria [5]. Such data 
were used historically during the Global Malaria Eradica-
tion Programme [6] and after [7–9] to monitor changes 
in transmission. There are several advantages to using 
serology in lower transmission settings where obtain-
ing precise estimates of PrP can be prohibitively expen-
sive. Serological assays such as ELISA are simple, quick 
and cheap to perform. Antibodies persist for months or 
years after infection, therefore, the effect of seasonality in 
transmission is smoothed out. Also, the longevity of anti-
bodies means that seroprevalence remains sufficiently 
high in low transmission settings to obtain meaningful 
estimates with achievable sample sizes. Serological data 
are typically analysed using catalytic models to estimate 
the antibody seroconversion rate (SCR)—the rate at 
which seronegative individuals become seropositive—
as a proxy for the force of infection [8, 9]. However, one 
limitation of this method is that it is necessary to distin-
guish seropositives from seronegatives using continuous 
measures of antibody levels. For malaria this is typically 
achieved using sera from European (i.e. unexposed) vol-
unteers to define a cut-off. However, there may be under-
lying differences between the immune responses in these 
unexposed volunteers and those living in endemic coun-
tries. An alternative approach is to fit mixture models 
to the bi-modal distribution of antibody levels [12–14]. 
However, this approach can be problematic in highly 
endemic areas where a large proportion of the population 
are seropositive.
Here is presented a continuous model of the acquisi-
tion and loss of antibodies which can be fitted to indi-
vidual-level data on measured antibody levels from cross 
sectional surveys. An advantage of this approach is that 
it takes into consideration the full information contained 
in measurement of antibodies levels rather than reducing 
the data to seropositive/seronegative status. Estimates 
of malaria transmission intensity are thus derived with-
out the use of cut-offs and with better precision than 
estimates obtained with binary seroprevalence data. The 
utility of the approach is illustrated by fitting the model 
to data from a cross-sectional survey in Tanzania across 
areas with differing endemicity and compare the results 
to traditional measures of malaria transmission intensity 
as well as to estimates obtained from catalytic models.
Methods
Data
Two age-stratified cross-sectional surveys were conducted 
in Tanzania. Individuals aged 0–46 years of age were sam-
pled from 12 villages across three altitudes transects in 
North Pare, South Pare and West Usambara. In each tran-
sect, villages were selected at high, medium and low alti-
tude, reflecting a range in malaria transmission intensity 
[10]. As infants may present with maternal antibodies, only 
individuals between one and 46  years were included in 
the analysis. Previous publications have already described 
the study design and epidemiology of malaria in this 
area [15]. Ethical approval was obtained from the insti-
tutional review boards of the National Institute of Medi-
cal Research of Tanzania, Kilimanjaro Christian Medical 
Centre, and the London School of Hygiene and Tropical 
Medicine. Individuals’ sera were collected and antibodies 
to the asexual stage merozoite antigens, Merozoite Surface 
Protein (MSP-119) and Apical Membrane Protein (AMA-
1), determined using ELISA [16]. Only anti-MSP-119 
antibodies were considered for these analyses, as these 
are assumed to be more immunogenic than anti-AMA-1 
antibodies [17–19]. Measurements were recorded as opti-
cal densities which were log-transformed prior to analysis 
with measurements below the limit of detection (LoD) 
assigned an approximate LoD of 0.01.
Density model
Model specification
A mathematical model was developed to describe the 
dynamics of acquisition and loss of antibodies in the pop-
ulation. The model assumes that, following exposure to 
an infectious bite which occurs at rate λ, an individual’s 
antibody level is boosted by δ(xt) where xt is the base-10 
logarithm of antibody density. In the absence of expo-
sure, antibodies are assumed to decay exponentially at a 
constant rate ρ. Let y(x, t) denote the proportion of the 
population with antibody level xat time t and K(x*, x) 
denote the probability that individuals with (log10) anti-
body level x at time t are boosted to level x*(x*  >  x) on 
exposure to an infectious bite between t and δt with K(x*, 
x) = 0 if x* ≤ x (∫x∞K(x*, x) dx* = 1). Then the distribution 
of antibody levels in the population is given by:
∂y(x, t)
∂t
=
∫ ∞
0

[
K (x, x∗), y(x∗, t)− K (x∗, x)y(x, t)
]
dx∗
+ ρ
∂y(x, t)
∂x
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With ∫λK(x, x*) y(x*) dx* corresponding to all the indi-
viduals with lower antibody levels who get boosted to 
level xupon exposure. Similarly ∫λK(x*, x) y (x)dx* corre-
sponds to the individuals with antibody levels xwho get 
boosted to a higher level upon exposure and ρ ∂y(x)
∂x  cor-
responds to the individuals losing their antibodies.
The model was numerically approximated by a version 
in which the log10 antibody density variable, x, was dis-
cretized by dividing the range of the variable into N com-
partments each of width D, with xi denoting the value 
of (log10) antibody density at the mid-point of antibody 
class i. The first class represents measurements below the 
LoD, xmin. Here N = 51, with D = 0.052 and xmin = −2. 
The resulting discrete model describes the dynamics of 
the proportion of the population in each antibody density 
category i, denotedyi, and is defined by the following set 
of ordinary differential equations:
where h, i, j index the N antibody level classes. The rates 
of exposure and decay of antibodies, λ and ρ, are assumed 
to be independent of antibody density and age. The 
probability that following exposure, antibody levels are 
boosted to class i from class j, kij, is distributed according 
to a discretized lognormal distribution:
where F(z, δ(x), S)is the cumulative density function at point 
z of the lognormal distribution with mean δ(x) and stand-
ard deviation S. δ(x) is the mean boost size, a function of the 
current log10 antibody level, x, assumed to be given by:
where a, b and η are parameters. This model assumes 
that exposure increases the log of antibody density by a 
decreasing amount as current density increases.
dyi
dt
= 
∑
j<i
i �=1
kijyj +
ρ
∆
yj+1 − 
∑
h>i
i �=N
khiyi−
ρ
∆
yi 1 ≤ i ≤ N
kij =


0 if i < j
F(xi +∆/2− xj; δ(xj), S)− F(xi −∆/2− xj; δ(xj), S) if j ≤ i < N
1− F
�
xN−1 +∆/2− xj; δ(xj), S
�
if i = N
δ(x) =
{
ae−bx if x > xmin
η otherwise
The model is run at equilibrium and constant malaria 
exposure over the years is assumed. As a result, age of 
individuals is considered as a proxy for time.
Parameter estimation
A Bayesian approach was used to estimate the model 
parameters, summarized in Table 1, by fitting the model 
to the data from the 12 villages simultaneously, allowing 
only the exposure, λv, to vary by village. The rate of decay 
of antibodies was fixed to 0.7 years−1. Using θ to denote 
the estimated parameter vector and D the data, the mul-
tinomial log-likelihood is given by:
Here ni,t,v and yi,t,v are, respectively, the observed number 
and predicted proportion of individuals in antibody category 
i in village v at age t. The differential equations were numeri-
cally integrated in C using the Runge–Kutta method [20]. 
MCMC methods (using a Metropolis–Hastings algorithm 
[21]) were used to calculate the posterior distribution of the 
parameters. As all parameters were strictly positive we used 
a log-normal random walk proposal density and assumed 
uniform priors on [0, max], where max was the maximum 
permitted value of each parameter as listed in Table 1. Two 
runs of 500,000 iterations were performed for each run of 
the MCMC algorithm with a burn-in period of 50,000 steps. 
Chain convergence was checked visually. The output was 
l = log(P(D|θ)) =
∑
v
∑
t �=0
∑
i
ni,t,v log(yi,t,v)
Table 1 Model parameters and their maximum values
Parameter Description Maximum value Estimates median (95 % CrI)
λv Rate of exposure for village v 100 See Table 2
a Maximum antibody boost size on exposure 10 0.242 (0.237–0.246)
b Slope of dependence of antibody boost on current log10 optical density 10 0.090 (0.035–0.121)
s Standard deviation for boost size distribution 10 0.018 (0.006–0.032)
η Mean boost for individuals with no current antibody 100 0.026 (0.025–0.029)
then recorded every 200 iterations to generate a sample from 
the posterior distribution. The standard deviation of the pro-
posal distribution was tuned in order to achieve appropriate 
mixing of the chains and an acceptance rate close to 20 % [22].
Catalytic model
A comparison of the estimates with those obtained using 
a previously described catalytic model [23] was per-
formed. In this simple model the proportion of individu-
als who are seropositive at age t is given by:
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where λC is the mean annual rate of conversion from 
seronegative to seropositive and ρC the mean annual rate 
of reversion from seropositive to seronegative. It should 
be noted that (for similar decay rates, r) the SCR esti-
mated with the catalytic model is expected to be smaller 
in absolute magnitude than the exposure rate calculated 
from the density model, as exposure in the density model 
may not always lead to an antibody boost sufficient to 
caused seroconversion by the criterion used in the cata-
lytic model. A Bayesian MCMC approach as described 
above was used for parameter estimation. The model 
was fitted to all villages simultaneously, again allowing 
λC to vary by village but with the constraint of estimat-
ing a single value forρC across all villages. Two methods 
were considered to define individual’s seropositivity. In 
the first a fixed cut-off value of antibody density of 0.5 
was used based on data from non-exposed European 
sera [10]. In the second a mixture model was fitted to the 
antibody level distribution for all the village’s data com-
bined across all age groups. The mixture model assumes 
that the population is composed of a subpopulation of 
seropositive individuals making up a proportion p of the 
whole population, and a seronegative subpopulation con-
taining the rest of the population. Antibody levels of indi-
viduals in each sub-population are normally distributed 
with parameters (μ1, σ1) for the seronegative group and 
(μ2, σ2) for the seropositive group. The parameters of the 
mixture model were estimated using MCMC methods 
with the following likelihood:
where Xi is the value of antibody levels Xi ∊ {X1, …, Xn} 
and φ(X, μ, σ) represents the probability density function 
for an observation X from a Normal distribution N  with 
mean μ and standard deviation σ. So that the overall dis-
tribution of antibody levels is (1 − p) N(μ1, σ12) + pN(μ2, 
σ22). For comparison with studies that use fixed cutoff, 
analyses were also conducted in which individuals with 
an antibody level greater than μ1  +  3σ1 are defined as 
seropositive.
Results
Data from 5227 individuals in the 12 villages were 
included in the analysis. The antibody levels of individ-
uals in each village stratified by age are shown in Fig. 1. 
The overall trend shows an increase in mean antibody 
level in adults in the village with decreasing altitude and 
hence increasing transmission intensity in this setting 
yc(t) =
c
c + ρc
[
1− e−(c+ρc)t
]
L(µ1, σ1,µ2, σ2, p;X) = Π
n
i=1{(1− p)φ(Xi,µ1, σ1)
+ pφ(Xi,µ2, σ2)}
[24–26]. As previously noted [10], two villages—Ngulu 
and Funta—have higher than expected antibody den-
sities, suggesting higher transmission despite being at 
medium altitude. As expected, the trend is for antibody 
density to increase with age in each village, representing 
cumulative exposure to infection.
The fitted density model is able to capture antibody 
density patterns across most of the villages (Fig.  1). In 
each transect, North Pare, South Pare and West Usam-
bara, our estimate of the exposure rate increased with 
increasing transmission intensity (as indicated by 
decreasing altitude), with the exception, as expected, of 
Ngulu and Funta villages (Fig. 2).
The maximum boost size, a, was estimated to be 0.242 
[95 % credible interval (CrI) 0.237–0.246] for individuals 
with antibody level above the detection threshold, and the 
slope of decline of boost with increasing current antibody 
level to be b = 0.09 (95 % CrI 0.035–0.121). As illustrated 
in Fig. 3, the low value of b means that the estimated anti-
body mean boost size declines approximately linearly 
with the current log10 antibody level. For the previously 
unexposed population, the mean boost size was estimated 
to be η = 0.026 (95 % CrI 0.025–0.029). The lack of over-
lapping CrIs for the estimates of a and η indicate that data 
allow us to distinguish the antibody responses of individu-
als who have never been exposed from those previously 
exposed who have low levels of antibodies.
A high correlation was observed between the estimates 
of exposure rates obtained using the density model, and 
that estimated by fitting a catalytic model to the data, 
using either European controls or a mixture model to 
derive the cut-off (see Fig.  4a). As anticipated, villages 
with high altitude (Bwambo, Kilomeni, Mpinji and Kwa-
doe) had lower estimates of exposure while villages with 
lower altitude (Kadando and Mgila) had higher esti-
mates of exposure, and this was consistent for estimates 
obtained with both the density and catalytic models.
One of the advantages of estimating the exposure rate 
using the density model rather than SCR is that it makes 
fuller use of the continuous nature of the data, thus 
potentially increasing inferential power. The coefficient of 
variation of the exposure rate estimates, a measure of the 
precision of those estimates, is consistently smaller for 
the density model estimates than for the catalytic model 
estimates (Fig. 4b), demonstrating an increase in the pre-
cision of the estimate of transmission intensity obtained 
by fitting a density model rather than a catalytic model. 
This result is more marked for villages with lower trans-
mission rates (higher altitude).
Figure  5 shows that the estimates of exposure rates 
were also highly correlated with the two different esti-
mates of the EIR available for the study villages (and 
listed in Table 2).
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Fig. 1 Antibody levels associated with age and village altitude for MSP-119 antigens. Black dots indicate median estimates of antibody density for 
the actual data for each village, while median and 95 % credible intervals are represented in red for the model fit (line for median and shaded area 
for the credible interval). In each transect (each column), villages are presented with decreasing altitude/increasing transmission intensity from top 
to bottom
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Fig. 2 Estimated exposure rate (median ± 95 % CrI) by village. In each transect (presented by boxes) North Pare, (a), South Pare (b) and West Usam-
bara, (c), the altitude for each village decreases from left to right and hence transmission intensity increases from left to right
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Fig. 3 The estimated dependence of the mean antibody boost size (δ) on the exposed individual’s current log10 antibody level. Its 95 % Credible 
Interval is represented by the shaded area. η denotes the antibody boost size for individual lacking current circulating antibodies (Median and 95 % 
CrI)
Page 7 of 11Pothin et al. Malar J  (2016) 15:79 
Discussion
The utility of serological data to measure malaria trans-
mission intensity has gained recognition in recent years 
[10, 11, 27] and is increasingly being incorporated in 
cross-sectional and longitudinal studies to monitor 
changes in transmission [28–32], identify “hotspots” of 
transmission [33–35] and to identify high risk groups 
[36]. One of the key advantages of the methods is their 
ease of use in the field, with new laboratory techniques 
enabling serological responses to multiple antigens to 
be made from dried blood spots that can be stored and 
transported without the need for refrigeration [37]. Clas-
sically the approach to analysing such data has been to 
distinguish seropositives from seronegatives using a cut-
off value informed by unexposed European control pop-
ulations [10, 11]. This has recognized limitations as the 
European control population may differ genetically in 
their immunological response to infection from the pop-
ulations being analysed [38]. To avoid the need to incor-
porate a cut-off independent of the antibody background 
level, a density model was developed and fitted to sero-
logical data from a malaria endemic setting in Northern 
Tanzania.
The results demonstrate that estimates of the expo-
sure rate obtained from fitting such models correlate 
highly both with previous estimates of the SCR obtained 
from the catalytic model as well as traditional measures 
of transmission intensity (the EIR) derived from alti-
tude or from PrP data [10, 39]. Overall, the model fits 
the field data very well though less for older individuals 
in some areas, perhaps due to the small sample size in 
this age group. Simulation studies (not presented here) 
also showed a good fit to the data. The model, therefore, 
provides an additional method to estimate transmission 
intensity from serological data that avoids the need to 
determine a cut-off between seropositivity and seron-
egativity disregarding the background antibody level. 
One alternative approach to using European controls to 
define a cut-off has been to using a mixture model [12, 
13]. Since this method can take into consideration the 
potential for misclassification of seropositive and seron-
egative individuals and in addition does not require an 
external dataset for standardization it provides an alter-
native appealing method for analysing serological data. 
However, one limitation of the mixture method approach 
is that it would not be appropriate in high transmission 
settings where the antibody distribution of seropositive 
and seronegative individuals becomes very difficult to 
distinguish. In contrast, the density model presented here 
performed equally well across all transmission settings.
An additional advantage of the density model over the 
catalytic model, as demonstrated here, is the improve-
ment in the precision of the estimate of transmission 
intensity obtained by fitting a density model compared 
with that obtained from fitting a catalytic model. In par-
ticular, this was notably better in the lower transmis-
sion settings. This is not surprising, as by using a density 
model we use a greater degree of information in the data. 
However, it is also relevant from a practical perspective, 
as serological measures are likely to be of greatest use 
0.50 0.55 0.60 0.65
−2.0
−1.5
−1.0
−0.5
log10 Exposure − Density model
lo
g 1
0 
E
xp
os
ur
e 
− 
C
at
al
yt
ic
 m
od
el
La
Mp
Go
Ta
KyS
Ka
Bw
Ki
Kw
Fu
Ng
Mg
European control: r= 0.95
Mixture model: r= 0.94
Mg
Ta
Fu
Kw
Ka
Go
Mp
Bw
KyS
Ng
La
Ki












North Pare
South Pare
West Usambara
0.00 0.05 0.10 0.15 0.20
Coefficient of variation
ba
Fig. 4 Comparison with seroconversion rate a Association of median estimates of exposure rates for different villages estimated using the antibody 
density model (x-axis) and the catalytic model (y-axis) using both European control (squares) and a mixture model to define the cut-off (circles). 
Note that the two measures are not equivalent but are highly correlated. b Plot of coefficient of variation (standard deviation of posterior/mean of 
posterior) of the exposure rate estimated from both the density model (black circles) and the catalytic model (x) using European controls. Data are 
presented for each village categorized by transect
Page 8 of 11Pothin et al. Malar J  (2016) 15:79 
in areas of low transmission intensity where other com-
monly used measures (in particular PrP) lack precision. 
Thus by utilizing the full data set, this increased precision 
is likely to improve the ability to distinguish temporal and 
spatial trends in settings in which malaria has recently 
fallen to low levels [40, 41] as well as to monitor low-level 
transmission in countries working towards local elimi-
nation of the parasite [42, 43]. The ability to determine 
significant changes in transmission such as drops in anti-
body levels would be an important development for the 
evaluation of interventions [44, 45]. However, a counter 
argument to this is that the difference in precision may 
not be attributable solely to more effective use of con-
tinuous data but reflects inherent uncertainty about how 
exposure translates into prevalence, incorporated in the 
SCR but not in the exposure rate derived with the density 
model.
The point of comparison for the newly developed den-
sity model was chosen to be what is commonly used in 
practice, i.e. methods deriving thresholds to define sero-
positivity [10, 27, 46–48]. However, mixture models have 
long been used to also avoid arbitrary misclassification 
and directly derive seroprevalences and SCRs [12, 49–
51]. Surprisingly these methods, despite being increas-
ingly studied in the field of malaria [52] have not yet been 
adopted as common practices.
Additionally, note that the rate of seroconversion from 
the catalytic model and exposure rate from the density 
model measure different quantities. Indeed, the expo-
sure rate measures the incidence of blood stage infec-
tions while the rate of seroconversion measures the rate 
at which individuals become seropositive, i.e. their anti-
body level increase above the cut-off value. One can, 
therefore, argue on the limited relevance in comparing 
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these estimates. However it is their correlation with 
exposure measurements, which is of particular interest 
for comparing transmission intensity from different set-
tings. Applying this approach to other serological data-
sets where additional measures of exposure are available 
is the obvious next step.
This model was developed using anti-MSP-1 antibodies 
as a proof-of-concept, as theses were assumed to be more 
immunogenic than other antibodies such as anti-AMA-1. 
However, such analysis could similarly be performed 
independently to other antibodies and the model could 
also be further developed to account for the dynamics of 
simultaneous antibodies.
Whilst the density model clearly has many advantages 
over the classical catalytic model, there are some limita-
tions are worth noting. Firstly the density model outlined 
here, whilst biologically grounded, is a simplistic repre-
sentation of the true process of antibody-acquisition and 
loss: it does not take into consideration more complex 
immune responses (such as interaction between anti-
body responses to different blood-stage antigens and/or 
between antibody- and cell-mediated immune responses 
[53]). Nevertheless, it would be interesting to check what 
effect, if any, incorporating these factors would have on 
the estimates of transmission as such data become avail-
able. Also, while providing a simplistic representation of 
the complex process, the model does not consider any 
age related changes in the affinity of the response [54, 
55] nor in the age dependency of biting rates [56]. Whilst 
such aspects are clearly important, they cannot be esti-
mated from cross-sectional data.
The process of loss of individual’s antibodies assumes 
a constant rate of decay of antibodies fixed to 0.7 years−1 
corresponding to a half-life around 360 days. This value, 
which originated from a longitudinal study [57], made 
the assumption that antibodies detected for serological 
studies produced by long lived plasma cells. However, 
short-lived antibody responses to merozoite antigens are 
mostly observed [55, 58, 59] and by ignoring these, the 
model might over-estimate antibody levels. Sensitivity 
analyses on the rate of decay (not presented here) have 
shown a high correlation with exposure rate. As a result, 
the absolute value for the exposure might not be accu-
rate depending on the assumption made for the rate of 
decay of antibodies but its usefulness in ranking settings 
according to their transmission intensity still remain.
Additionally, fitting a density model to serological data 
is computationally intensive and this may limit its wider 
utility. However, this can to some extent be overcome 
given the wider availability of statistical packages that can 
be used to perform such analyses and through sharing 
of code. To this end the R code used for this analysis is 
available from the authors on request. For wider use, the 
practicalities of the assay generating the serological data 
would need to include a strong component of standardi-
zation for the data between laboratories or conducted at 
different times to be compared confidently.
Conclusion
In summary, the density model presented here pro-
vides a new method for analysing serological data that 
complements existing widely utilized tools for measur-
ing malaria transmission intensity. No gold standard 
method has yet been developed for estimating exposure 
from serological data and this newly develop model 
represents an additional approach to do this. However, 
Table 2 Summary of study data
PrP denotes parasite prevalence measured with microscopy in children 0–4 years of age
EIR1  is estimated from altitude [EIR = 331.5 exp (−0.0057 × altitude) [10]]
EIR2  was estimated from the parasite prevalence data using a previously published relationship [39]
Transect Village Altitude N PrP EIR1 EIR2 Estimated λv median (95 % CrI)
North Pare Kilomeni (Ki) 1556 411 1 0.047 0.08 3.087 (2.995–3.178)
Lambo (La) 1188 355 10 0.38 1.11 3.287 (3.195–3.379)
Ngulu (Ng) 832 486 8 2.9 0.84 4.109 (4.004–4.217)
Kambi ya Simba (KyS) 746 494 10 4.7 1.11 4.071 (3.972–4.173)
South Pare Bwanbo (Bw) 1598 485 3 0.037 0.26 3.085 (3.001–3.174)
Mpinji (Mp) 1445 461 2 0.088 0.17 3.071 (2.983–3.158)
Goha (Go) 1163 453 13 0.44 1.57 3.522 (3.437–3.607)
Kadando (Ka) 528 382 25 16 4.45 4.339 (4.212–4.477)
West Usambara Kwadoe (Kw) 1564 357 4 0.045 0.37 3.138 (3.037–3.236)
Funta (Fu) 1240 429 17 0.28 2.38 4.364 (4.243–4.494)
Tamota (Ta) 1055 449 19 0.81 2.74 3.857 (3.765–3.95)
Mgila (Mg) 375 465 34 39 8.31 4.326 (4.198–4.463)
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future development of this method is needed to test it 
against a wider set of transmission settings, incorpo-
rate methods for assessing spatial and temporal varia-
tions in exposure and to assess its utility in capturing 
changes in transmission following scaling up of malaria 
interventions.
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